BY-103 prodrug

• Treatment for various blood cancers.
• Oral administration with formation of the original parent drug in the human gastrointestinal tract.
• Multiple patents pending.
• Possibly to carry out Phase 1 clinical trials in Australia, bypassing pre-clinical animal studies and trials.
• Combination use with other oral or non-oral anti-cancer treatments.
• Primary choice to work in conjunction with apoptosis-driven anti-cancer treatments.
• Applicable with USFDA 505 (b)(2) for new drug pathway.

Current status

• Pre-clinical preparation